KSQ-4279, a first-in-class USP1 inhibitor shows strong combination activity in BRCA mutant cancers with intrinsic or acquired resistance to PARP inhibitors-MedSci.cn

KSQ-4279, a first-in-class USP1 inhibitor shows strong combination activity in BRCA mutant cancers with intrinsic or acquired resistance to PARP inhibitors

Cadzow, L; Gokhale, PC; Ganapathy, S; Sullivan, P; Nayak, S; Shenker, S; Schlabach, M; Tobin, E; Matulonis, UA; Liu, JF; Stegmeier, F; Wylie, A

EUROPEAN JOURNAL OF CANCER, 2022; 174 (): S37

科室
- - 订阅+
  - 更多科室
工具
服务